

Freedom of Information Act 2000 - Request Reference FoI/23/515

Coagulation Factors

Information Requested:

I would like to submit an FOI request for the following coagulation factors product:

1. How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in Q3'23 (July, August, September 2023)?
 - a. With BPA/Hemlibra Inhibitor?
2. Please fill in the BPA/Hemlibra products *utilized* in July, August, and September 2023.

July 1st through September 2023		Q3'23 Volume (IU)/mg	Total Patients	Patients	
				Prophylaxis	On demand
	<i>Example: FEIBA</i>	<i>50,000 IU</i>	<i>1</i>	<i>0</i>	<i>0</i>
Hem A Inhibitor Patients					
Haem A Inhibitor Patients	FEIBA				
	Cevenfacta				
	NovoSeven				
	Hemlibra				
Hem B Inhibitor Patients					
Haem B Inhibitor Patients	FEIBA				
	Cevenfacta				
	NovoSeven				
	Obizur				
AHA Patients					
AHA Patients	FEIBA				
	NovoSeven				
	Obizur				
	Cevenfacta				
	Hemlibra				
Other Use					
FVII deficient	NovoSeven				
Glanzmann's	NovoSeven				
Other	NovoSeven				
Other	Cevenfacta				

3. How **many** minor and major surgeries did your BPA patients have in July, August, and September 2023?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

4. How **many** minor and major surgeries did your BPA/Hemlibra inhibitor patients have in July, August, and September 2023??

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

5. How many **breakthrough bleeds** did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	Inhibitor patients	Q3'23 volume (IU/mg)
Hemlibra		
NovoSeven		
FEIBA		

6. Were there any changes in the total number of acute bleeds treated with factor in Q3'23 as compared to Q2'23?

7. Was there any change in the number of elective surgeries **using factor** in Q3'23 as compared to Q2'23?

<i>Number of Surgeries</i>	<i>BPA</i>
Increase / Decrease / Stable compared to Q2'23?	
How many surgeries occurred in Q3'23?	

8. Have any BPA patients switched products between July 1st through September 30th 2023? What were the reasons for the switches?

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
<i>Example: Haem B Inh.</i>	<i>1 NovoSeven</i>	<i>On-demand</i>	<i>Cevenfacta</i>	<i>Prophy 1x/week</i>	<i>Severe</i>	<i>Patient requested to try out a new product to improve treatment</i>

9. What is the total number of patients treated with NovoSeven at your center?

Response Details:

In response to questions 1-9:

After considering your request, the UHB believes that Section 40 of the Freedom of Information Act 2000 applies. Due to the low numbers of individuals involved, the UHB believes that, when considered with other information already available within the public domain, disclosure would result in the risk of individuals becoming identifiable. The data requested is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.